Atlas Capital Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $998K | Sell |
4,707
-245
| -5% | -$48.1K | 0.11% | 158 |
|
|
2026
Q1 | $970K | Hold |
4,952
| – | – | 0.11% | 155 |
|
|
2025
Q4 | $859K | Buy |
+4,952
| New | +$902K | 0.1% | 180 |
|
|
2025
Q2 | $889K | Sell |
4,950
-29
| -0.6% | -$5.04K | 0.11% | 166 |
|
|
2025
Q1 | $842K | Buy |
4,979
+20
| +0.4% | +$3.29K | 0.11% | 166 |
|
|
2024
Q4 | $748K | Sell |
4,959
-28
| -0.6% | -$4.36K | 0.1% | 175 |
|
|
2024
Q3 | $774K | Buy |
4,987
+259
| +5% | +$38.7K | 0.12% | 155 |
|
|
2024
Q2 | $647K | Sell |
4,728
-139
| -3% | -$19K | 0.08% | 197 |
|
|
2024
Q1 | $648K | Sell |
4,867
-650
| -12% | -$84.3K | 0.1% | 180 |
|
|
2023
Q4 | $761K | Sell |
5,517
-86
| -2% | -$11.3K | 0.11% | 151 |
|
|
2023
Q3 | $683K | Hold |
5,603
| – | – | 0.11% | 146 |
|
|
2023
Q2 | $788K | Hold |
5,603
| – | – | 0.12% | 133 |
|
|
2023
Q1 | $793K | Hold |
5,603
| – | – | 0.12% | 125 |
|
|
2022
Q4 | $877K | Hold |
5,603
| – | – | 0.15% | 118 |
|
|
2022
Q3 | $687K | Sell |
5,603
-43
| -0.8% | -$5.66K | 0.13% | 134 |
|
|
2022
Q2 | $751K | Hold |
5,646
| – | – | 0.13% | 134 |
|
|
2022
Q1 | $773K | Buy |
5,646
+2,790
| +98% | +$389K | 0.12% | 152 |
|
|
2021
Q4 | $494K | Hold |
2,856
| – | – | 0.07% | 215 |
|
|
2021
Q3 | $415K | Hold |
2,856
| – | – | 0.07% | 230 |
|
|
2021
Q2 | $377K | Hold |
2,856
| – | – | 0.06% | 255 |
|
|
2021
Q1 | $367K | Sell |
2,856
-81
| -3% | -$9.98K | 0.07% | 233 |
|
|
2020
Q4 | $350K | Sell |
2,937
-3,084
| -51% | -$376K | 0.07% | 231 |
|
|
2020
Q3 | $689K | Sell |
6,021
-154
| -2% | -$18.2K | 0.16% | 135 |
|
|
2020
Q2 | $704K | Buy |
6,175
+55
| +0.9% | +$5.83K | 0.17% | 134 |
|
|
2020
Q1 | $491K | Buy |
6,120
+1,025
| +20% | +$106K | 0.15% | 156 |
|
|
2019
Q4 | $544K | Hold |
5,095
| – | – | 0.14% | 181 |
|
|
2019
Q3 | $545K | Buy |
5,095
+3,028
| +146% | +$311K | 0.16% | 178 |
|
|
2019
Q2 | $210K | Hold |
2,067
| – | – | 0.07% | 285 |
|
|
2019
Q1 | $186K | Sell |
2,067
-4,414
| -68% | -$382K | 0.07% | 274 |
|
|
2018
Q4 | $540K | Sell |
6,481
-362
| -5% | -$33.9K | 0.22% | 124 |
|
|
2018
Q3 | $727K | Buy |
6,843
+3,241
| +90% | +$355K | 0.24% | 115 |
|
|
2018
Q2 | $411K | Sell |
3,602
-3,431
| -49% | -$357K | 0.15% | 184 |
|
|
2018
Q1 | $705K | Buy |
+7,033
| New | +$720K | 0.22% | 148 |
|
Other funds holding DGX
EIG
Atlas Capital Advisors's DGX Position: Q2 2026 in Review
Atlas Capital Advisors reduced its Quest Diagnostics (DGX) stake by 4.9% in Q2 2026, selling an estimated $48.1K and leaving 4,707 shares worth $998K. The position accounts for 0.11% of the portfolio, ranked #158.
Atlas Capital Advisors first reported a position in DGX in Q1 2018 and has held it in 33 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Atlas Capital Advisors held 4,707 shares of Quest Diagnostics worth $998K as of Q2 2026.
- Atlas Capital Advisors sold 245 Quest Diagnostics shares in Q2 2026, an estimated $48.1K.
- Quest Diagnostics made up 0.11% of Atlas Capital Advisors's portfolio in Q2 2026, its #158 holding.
- Atlas Capital Advisors first reported a position in Quest Diagnostics in Q1 2018 and has held it in 33 quarters since.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.